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Introduction
The Patient Protection and Affordable Care Act signed by President Obama in March 2010 emphasized improving the quality and efficiency of the health care system. 1 One piece of this reform involves developing and evaluating payment bundling by an episode of hospitalization (defined as all care 3 days prior to hospitalization through 30 days following discharge). In addition, Medicare is considering ways to penalize hospitals with high readmission rates. 2 Thus it is increasingly important to minimize cost and utilization, not only during the hospitalization, but also in the 30 days post-discharge. According to data collected by the Healthcare Cost and Utilization Project, 15% of all patients admitted to hospitals in the United States (U.S.) in 2009 had diabetes. 3 Because inpatient stays account for the largest proportion of health care expenditure for diabetes (44%), followed distantly by nursing home stays (15%) and office visits (11%), 3 decreasing 30-day hospital readmission rates among patients with diabetes is paramount in controlling health care costs in this new bundled world.
Readmission rates among patients with diabetes are substantial. Existing literature shows that 30-day readmission rates range from a low of 7.7% among the commercially insured to a high of 20% among Medicare and Medicaid patients. 4, 5 Studies have shown that up to 55% of hospital readmissions may be due to inappropriate inpatient care or poor discharge planning and, thus, are preventable. [6] [7] [8] [9] Robbins and Webb 5 demonstrated that the absence of a diabetes diagnosis in the hospital discharge record in patients with known diabetes was a highly significant predictor of hospitalization after adjustment. Failure to code a diabetes diagnosis in administrative data suggests that the diabetes-specific needs of the patient were not met during hospitalization and no attention was given to diabetes-specific discharge planning. These findings strongly support that highquality inpatient care and attention to diabetes discharge planning can reduce the likelihood of readmission.
However, questions remain as to whether receipt of highquality outpatient care can have a significant impact on 30-day hospital readmissions. A study by Chen and colleagues 10 found that receipt of two quality care processes, hemoglobin A1c (HbA1c) and lipid monitoring, in the previous year reduced the risk of hospitalization by 20% in the following year. 10 Another study by Stuart and associates 11 found a strong association between persistence of medication use and risk of hospitalization. Each additional prescription filled by users of oral antidiabetic agents decreased the risk of hospitalization by 0.3%, while each additional prescription filled of an angiotensin receptor blocker (ARB) reduced risk of hospitalization by 1.3%. Furthermore, every additional angiotensin-converting enzyme inhibitor (ACEI) prescription filled reduced the risk of hospitalization by 0.9% and additional 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (statin) prescriptions filled lowered the risk of hospitalization by 0.5%. There is no direct research on the impact of these outpatient quality practices on readmission.
The objective of this study is to assess the impact of outpatient quality of care on 30-day hospital readmission rates among commercially insured patients with diabetes. Since the Institute of Medicine has recommended qualitybased incentive programs as a mechanism to better align payment and quality in the United States, the Centers for Medicare and Medicaid Services, state governments, and a majority of payers have implemented outpatient quality initiatives. [12] [13] [14] As the flurry of outpatient quality initiatives continues, it is important to understand the potential impact of outpatient quality of care on the likelihood of hospital readmission.
Methods
We used administrative claims data from the IMS LifeLink Database (formerly PharMetrics), encompassing both feefor-service and managed-care coverage. The LifeLink population is representative of the U.S. commercially insured population in terms of age, gender, and type of health plan. Data were deidentified in compliance with the Health Portability and Accountability Act. For this study, we used data from approximately 12 million unique members from over 30 health plans living in all regions of the United States in 2010. Membership and health plan eligibility information were linked to claims from inpatient, outpatient, professional, emergency department, and ancillary sources. Data elements drawn from these databases included member demographics (age, gender, residence region, and enrollment), service dates, setting of care (outpatient, inpatient, or emergency room), diagnosis codes, procedure codes, and outpatient pharmacy (retail and mail-order prescriptions) claims.
Study Selection
This study included patients 19 years and older who were discharged from the acute inpatient setting with diabetes (ICD-9 diagnosis codes: 249.xx, 250.xx, 357.2, 362.0x, 366.41) between December 1, 2009, and November 30, 2010. Of note, the diagnosis of diabetes did not need to be the principal discharge diagnosis. To accurately assess both the baseline clinical characteristics prior to the hospital admission and the outcome of interest (i.e., 30-day hospital readmission), the study only included patients who were continuously enrolled in the health plan for medical and pharmacy benefits during the year prior to the admission date through 30 days after the discharge date (n = 30,139).
Outcome Variable
The outcome of this study was hospital readmission for any diagnosis in the 2-30 days after discharge. We did not include readmission 0-1 days after discharge because of the difficulty differentiating between transfer to another facility and inpatient readmission using commercial administrative claims data.
Main Independent Variables
The main independent variables we assessed include receipt of outpatient quality of care in the year prior to admission [i.e., two or more HbA1c lab tests (yes/no), one or more low-density lipoprotein (LDL) tests (yes/ no), ≥90 days supply for a statin, and ≥90 days supply for ACEIs or ARBs]. We measured a 90-day supply of these medications because we wanted to capture the concept of medication adherence instead of just a onetime prescription.
Covariates
The covariates included demographics (i.e., age, gender, region, and health plan), clinical characteristics (i.e., Elixhauser comorbidities, any insulin use), health care utilization, and insurance type in the year prior to admission. We did not present information by health plan because of concerns regarding confidentiality. Elixhauser comorbidities is specifically adapted for administrative data sets and have been shown to predict a variety of patient outcomes, including mortality, length of stay, and hospital charges. 15 We measured any insulin use (yes/no) as a proxy of diabetes severity; the hypothesis is that patients with more severe diabetes require insulin. Health care utilization in the year prior to admission included number of outpatient visits, hospitalization (yes/no), and emergency room use (yes/no). We controlled for the following insurance types: health maintenance organization, preferred provider organization, and other.
Statistical Analysis
Univariate descriptive statistics were calculated for all independent variables. Bivariate statistical tests (i.e., chisquare) were conducted to test significant differences in patient characteristics by readmission (yes/no). Multivariate logistic regression modeling was used to examine the impact of outpatient quality of care (i.e., two HbA1c tests, LDL test, 90-day supply of statin, and 90-day supply of ACEI/ARBs) on hospital readmission while controlling for covariates. We included health plan fixed effects to eliminate the variation in readmission across plans. All variables were assessed for colinearity prior to their inclusion in the final model. Because region was highly colinear with health plan (r = 0.87), we dropped region from the multivariate model. The results are presented as odds ratios (ORs), 95% confidence intervals (CIs), and p values. A p value of 0.05 was considered to be significant. SAS ® Proprietary Software, Release 9.1 (SAS Institute Inc., Cary, NC), was used for all statistical analyses.
Results
The overall 30-day readmission rate among patients with diabetes was 18.9%. The majority of patients in the hospitalized diabetes cohort were 55 years and older (72.41%; Table 1 ). Older patients were significantly more likely to be readmitted in both the bivariate ( Table 2 ) and the multivariate ( diabetes. Number of outpatient visits in the year prior to admission had no significant impact on the likelihood of readmission when controlling for other patient characteristics.
Patients who received both quality processes of care (i.e., two HbA1c and LDL tests) in the year prior to admission were significantly less likely to be readmitted to the hospital in the bivariate analysis (p < .001; Table 2 ]. However, when controlling for other patient characteristics, only patients who received an LDL test in the year prior to admission were significantly less likely to be readmitted to the hospital (OR = 0.918, 95% CI [0.852 0.989], p < .025; Table 3 ). Patients who filled at least a 90-day supply of a statin in the year prior to admission were significantly less likely to be readmitted to the hospital (OR = 0.91, 95% CI [0.85 0.97], p < .01; Table 3 ). Conversely, patients who filled at least one prescription for insulin were significantly more likely to be readmitted to the hospital (OR = 1.20, 95% CI [1.12 1.28], p < .001).The majority of patients in our analysis were in the preferred provider organization insurance type. Insurance types were not a significant predictor of readmission in the multivariate analysis. 
Discussion
The 30-day hospital readmission rate among commercially insured patients in this study (18.9%) was higher than those reported in prior studies of commercially insured populations (7.7-11.6%) 4, 5 but was in line with a study of the Medicaid and Medicare population (21.2-23.3%). 5 This rate may be more in line with rates reported of Medicare populations, because 40% of the patients in this study were 65 years and older (mean age = 63.0 years) and have Medicare plus commercial insurance.
We found in this study that patients who filled at least a 90-day supply of a statin medication were significantly less likely to be readmitted to the hospital. This may be because most 30-day readmissions among patients with diabetes were associated with exacerbations of vascular disease, and a robust randomized control trial, the Heart Protection Study, has shown that statin therapy was associated with a 22-33% reduction in cardiovascular events among all patients with diabetes, regardless of history of vascular disease. 16 What is most interesting is that we found that patients who received a standard quality-of-care intervention consisting of at least one LDL test as an outpatient in the year prior to hospital admission were also significantly less likely to be readmitted to the hospital in the 30 days post-discharge. This is important because the receipt of at least one LDL test among patients with diabetes is one of the Healthcare Effectiveness Data and Information Set (HEDIS) diabetic process of care measures that is used widely by qualitybased incentive programs such as pay for performance or transparency programs. Although a majority of payers have adopted some form of quality-based incentive program, the evidence for the effectiveness of these programs to impact outcomes has been scant. This study suggests that quality-based incentive programs, including the receipt of at least annual LDL testing among patients with diabetes, can lead to reduced rates of 30-day hospital readmission.
We did not find significant association between receipt of HbA1c testing, another commonly used HEDIS diabetic process of care measure, and the reduction of 30-day hospital readmission. This may be because good glycemic control is difficult to achieve, a long period of tight glycemic control may be needed to see its benefit, and the receipt of HbA1c testing is only first of many steps in achieving good glycemic control.
Unlike Stuart and associates, 11 who found a significant reduction in hospitalization associated with persistence of ACEI/ARBs, we did not find a significant reduction in 30-day readmission among diabetes patients who received at least 90 days of ACEI/ARBs. This may be because the benefit of ACEI/ARBs among patients with diabetes is strongest for subgroups of high-risk diabetes patients, mainly those with existing cardiovascular disease, heart failure, 17, 18 or diabetic nephropathy, 19 and the evidence for reduction of cardiovascular events among diabetes patients in general is conflicting. 20, 21 There are some limitations to consider. First, this is an administrative-claims-based data analysis, with potential biases secondary to coding variation and missing data. However, administrative claims data have been used successfully in many studies to examine patterns, effectiveness, and gaps in quality of care and assess outcomes in care. [22] [23] [24] [25] Second, although the IMS LifeLink Database is a fairly comprehensive database, it is only representative of a commercially insured population. The findings of this study cannot be generalized to other populations, specifically Medicaid and the uninsured. Lastly, there were unmeasured factors that predict hospital readmission (e.g., quality of inpatient care and discharge planning, race, education, blood pressure control, HbA1c and LDL levels, smoking, obesity) that were not controlled for in the multivariate analyses.
Conclusions
We found that patients who received at least a 90-day supply of statins or an LDL test as an outpatient in the year prior to hospital admission were significantly less likely to be readmitted to the hospital within 30 days. This is a strong affirmation to the value of statins among all patients with diabetes in the real world outside the confines of a rigorous randomized control trial. In addition, this finding should be good news for the majority of payers that adopted some form of quality-based incentive program to target the increase receipt of LDL testing for patients with diabetes. Findings of this study also suggest that incentive-based quality programs to increase the use of and adherence to statins among all patients with diabetes regardless of LDL level may be worthy of consideration. Although we did not find a positive association between receipt of HbA1c testing and decreased likelihood of hospital readmission, future studies can focus on HbA1c control and hospital readmission. Similarly, although we did not find a positive association between persistence of ACEI/ARB and decreased likelihood of readmission among all patients with diabetes, future studies should focus on the benefit of ACEI/ARB among the subpopulation of diabetes patients with diabetic nephropathy or heart failure on hospital readmission.
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